NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BBLG

Bone Biologics Corp

Jul 01 • 04:00PM ET

3.68

Dollar change -0.35
Percentage change -8.68	%

Healthcare • Medical Devices • USA • NASD

Peers: JNJ SYK MDT BAX SNN ZBH GMED IART OFIX ATEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-23.25	Insider Own	0.12%	Shs Outstand	0.55M	Perf Week	-33.74%
Market Cap	2.01M	Forward P/E	-	EPS next Y	-1.93	Insider Trans	0.00%	Shs Float	0.54M	Perf Month	-30.31%
Enterprise Value	-0.74M	PEG	-	EPS next Q	-0.58	Inst Own	0.80%	Short Float	5.53%	Perf Quarter	-23.33%
Income	-7.48M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.06	Perf Half Y	-35.44%
Sales	0.00M	P/B	0.69	EPS next Y	-	ROA	-121.79%	Short Interest	0.03M	Perf YTD	-34.77%
Book/sh	5.34	P/C	0.73	EPS next 5Y	79.61%	ROE	-129.48%	52W High	25.50 -85.57%	Perf Year	-49.37%
Cash/sh	5.04	P/FCF	-	EPS past 3/5Y	61.58% 55.67%	ROIC	-256.83%	52W Low	3.42 7.60%	Perf 3Y	-99.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	23.21% 15.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	82.88%	Oper. Margin	-	ATR (14)	0.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.59	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.59	EPS Q/Q	75.61%	SMA20	-24.97%	Beta	-	Target Price	22.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-21.02%	Rel Volume	0.90	Prev Close	4.03
Employees	2	LT Debt/Eq	0.00	Earnings	May 28	SMA200	-44.04%	Avg Volume	475.26K	Price	3.68
IPO	Mar 31, 2016	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	427,613	Change	-8.68%

Jun-30-25 04:10PM	Bone Biologics Announces Closing of $5.0 Million Public Offering (Business Wire) -12.01% -8.68%
Jun-27-25 09:10AM	Bone Biologics Announces Pricing of $5.0 Million Public Offering (Business Wire) +10.10%
07:00AM	Bone Biologics Files Patent Application for Bone Regeneration Technology (Business Wire)
Jun-26-25 04:20PM	Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements (Business Wire)
Jun-06-25 08:00AM	Bone Biologics Announces 1-for-6 Reverse Stock Split (Business Wire)
08:00AM	Loading…
Oct-21-24 08:00AM	Bone Biologics Appoints Phillip T. Meikle to its Board of Directors (Business Wire)
Sep-04-24 08:00AM	Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +5.17%
Aug-02-24 08:00AM	Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds (Business Wire)
Jun-21-24 08:35AM	Life Science Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Jun-20-24 08:00AM	First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion (Business Wire) -14.09%
Jun-18-24 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for June 20th (GlobeNewswire)
Jun-17-24 08:00AM	Bone Biologics Executives to be Interviewed in a CEO Chat by Zacks Small-Cap Research Analyst on June 20th (GlobeNewswire)
Jun-05-24 07:35AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 09:55AM	BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024 (InvestorPlace)
Mar-06-24 04:15PM	Bone Biologics Announces Closing of $2.0 Million Public Offering (Business Wire)
09:15AM	Loading…
Mar-04-24 09:15AM	Bone Biologics Announces Pricing of $2.0 Million Public Offering (Business Wire)
Mar-01-24 08:00AM	Bone Biologics Reports Progress With NB1 Clinical Program (Business Wire)
Jan-11-24 08:00AM	Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors (Business Wire)
Jan-10-24 08:00AM	Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements (Business Wire)
Dec-20-23 11:03AM	BBLG Stock Earnings: Bone Biologics Misses EPS for Q1 2023 (InvestorPlace)
Dec-18-23 08:00AM	Bone Biologics Announces 1-for-8 Reverse Stock Split (Business Wire)
Nov-20-23 12:38PM	Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Business Wire)
Nov-17-23 08:37AM	Why Is Bone Biologics (BBLG) Stock Down 38% Today? (InvestorPlace) -21.79%
Nov-16-23 04:43PM	Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Business Wire) +43.62%
07:46AM	Why Is Bone Biologics (BBLG) Stock Up 84% Today? (InvestorPlace)
Sep-26-23 08:00AM	Bone Biologics Provides Scientific Update on NB1 Bone Graft Device (Business Wire)
Sep-15-23 03:02AM	Insider Buying: CFO Deina Walsh Acquires 8,000 Shares of Bone Biologics Corp (BBLG) (GuruFocus.com)
Sep-13-23 05:01AM	CEO Jeff Frelick Buys 9,500 Shares of Bone Biologics Corp (BBLG) (GuruFocus.com)
Aug-15-23 08:43AM	BBLG Advances Crucial Technology and Solidifies Funding (Zacks) -35.02%
Jun-14-23 11:30PM	Bone Biologics Prices $5.0 Million Underwritten Public Offering (Business Wire) -14.19% -58.27%
06:15AM	Loading…
Jun-08-23 06:15AM	BBLG: BBLG Advances Crucial Technology and Solidifies Funding (Zacks Small Cap Research) +7.04%
Jun-06-23 01:00PM	Bone Biologics Effects 1-for-30 Reverse Stock Split (Business Wire)
May-16-23 07:20AM	BBLG: BBLG Has Solid Cash and Is Advancing Testing (Zacks Small Cap Research)
Apr-11-23 08:27AM	BBLG: Bone Biologics Announces the Approval of A Vital Trial (Zacks Small Cap Research)
08:00AM	Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia (Business Wire)
Mar-17-23 06:29AM	BBLG: BBLG Provides Investment Opportunity Before Trials (Zacks Small Cap Research) -5.60%
Jan-26-23 08:30AM	Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization (Business Wire) -9.31%
Nov-15-22 06:10AM	BBLG: A Potential Game-Changer for Back Surgeries (Zacks Small Cap Research) +13.97%
Oct-25-22 08:00AM	Bone Biologics CEO Issues Letter to Stockholders (Business Wire)
Oct-13-22 09:00AM	WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering (PR Newswire) -9.55%
Oct-12-22 04:05PM	Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering (Business Wire)
Oct-07-22 10:52AM	CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering (Business Wire) -35.53%
10:16AM	WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering (PR Newswire)
Sep-15-22 06:20AM	BBLG: Market opportunity for Bone continues to grow. (Zacks Small Cap Research) +10.08%
Jun-07-22 07:23AM	BBLG: Bone Biologics Set up For Success (Zacks Small Cap Research)
Mar-23-22 08:00AM	Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (Business Wire) +5.35%
Mar-18-22 07:25AM	We're Hopeful That Bone Biologics (NASDAQ:BBLG) Will Use Its Cash Wisely (Simply Wall St.) +26.27%
07:15AM	BBLG: Bone Biologics Inks Important Supply Agreement (Zacks Small Cap Research)
Mar-07-22 07:00AM	Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix (Business Wire) -6.25%
Feb-24-22 06:00AM	BBLG: Back Pain Solution Potentially on the Way (Zacks Small Cap Research) -6.31%
Jan-10-22 03:50PM	BBLG Stock Alert: 7 Things to Know as Bone Biologics Skyrockets Today (InvestorPlace) +57.14%
10:38AM	Why Are Bone Biologics Shares Surging On Monday? (Benzinga)
Jan-05-22 08:30AM	Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference (Business Wire)
Nov-17-21 06:43AM	25 Stocks Moving in Wednesday's Pre-Market Session (Benzinga)
Nov-16-21 06:49AM	36 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Nov-10-21 09:15AM	BBLG: Bone Biologics (Zacks Small Cap Research)
Nov-02-21 07:26AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:04AM	24 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Oct-18-21 08:30AM	Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq (Business Wire)
Oct-15-21 12:00PM	WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering (PR Newswire)
Oct-13-21 01:43PM	WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market (PR Newswire) -72.85%
12:25PM	Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split (Business Wire)

Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BBLG

Bone Biologics Corp

Upgrade your FINVIZ experience